Highlights From the 2017 ESMO Congress
  • CME

September 8-12, 2017; Madrid, Spain
In this text module and accompanying downloadable slideset, experts review key study results presented at the 2017 ESMO annual meeting across multiple malignancies including advanced NSCLC, breast cancer, bladder cancer, renal cell carcinoma, gastric/gastroesophageal cancer, HNSCC, and hepatocellular carcinoma.
Richard Finn, MD
Leora Horn, MD, MSc, FRCPC
Yelena Y. Janjigian, MD
Joyce O'Shaughnessy, MD
Elizabeth R. Plimack, MD, MS
Tanguy Seiwert, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: October 31, 2017 Expiration: October 30, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with cancer
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Discuss new data on novel agents and therapeutic approaches for patients with cancer
  • Consider how new trial findings might affect treatment of cancer in clinical practices in the future

Acknowledgements

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by educational grants from
AbbVie
AstraZeneca
Eisai
Lilly
Merck & Co., Inc.
Puma Biotechnology

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Richard Finn, MD

Associate Professor of Medicine
Division of Hematology-Oncology
Director, Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

Richard Finn, MD, has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Eisai, and Pfizer.
Leora Horn, MD, MSc, FRCPC

Ingram Associate Professor of Cancer Research
Director
, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, and Xcovery and fees for non-CME services from Boehringer Ingelheim.
Yelena Y. Janjigian, MD

Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD, has disclosed that she has received consulting fees from Astellas, Bristol-Myers Squibb, Lilly, Merck, and Serono, and funds for research support from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Lilly, Merck, and Pfizer.
Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Director,
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AstraZeneca, Lilly, Novartis, and Pfizer.
Elizabeth R. Plimack, MD, MS

Chief, Division of Genitourinary Medical Oncology
Director, Genitourinary Clinical Research
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Clovis, Exelixis, Genentech, Horizon Pharma, Inovio, Lilly, Novartis, Pfizer, and Roche and funds for research support from Agensys, AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Peloton, and Pfizer.
Tanguy Seiwert, MD

Assistant Professor, Department of Medicine
Associate Director, Head and Neck Cancer Program
Section of Hematology/Oncology
Fellow, Institute for Genomics and Systems Biology
University of Chicago
Chicago, Illinois

Tanguy Seiwert, MD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, and Merck and funds for research support from Bristol-Myers Squibb, Innate Pharma, Jounce, and Merck.

Staff

Rachael M. Andrie, PhD

Associate Managing Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with cancer.

Goal

The goal of this activity is to improve participants’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with cancer.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 31, 2017, through October 30, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

Related Content

Watch a CME/CE-certified Webcast of an ASCO 2018 symposium where John L. Marshall, MD, leads an expert panel reviewing the top 10 oncology biomarkers.

John L. Marshall, MD
Program Director
Todd M. Bauer, MD Hagop M. Kantarjian, MD Edward S. Kim, MD, FACP Andrew D. Zelenetz, MD, PhD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Registered Nurses: 2.0 Nursing contact hours Released: July 10, 2018 Expiration: July 9, 2019

Expert commentary from Manish A. Shah, MD, on recent developments in targeting cancer stem cells in gastrointestinal cancers, including data from ASCO 2018.

Manish A. Shah, MD Released: June 28, 2018

Frankie Ann Holmes, MD, FACP, discusses the potential implications of new data from the Persephone and PerELIZA trials in HER2-positive early breast cancer.

Frankie Ann Holmes, MD, FACP Released: June 22, 2018

Immune checkpoint inhibitors (ICIs) have expanded treatment options for patients who cannot tolerate chemotherapy. Read my thoughts on using ICIs in clinical practice, as well as some of the most promising salvage strategies for patients who progress on them.

Daniel P. Petrylak, MD Released: June 20, 2018

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?